




GastroPlus® X.2

Easier. Faster. More Powerful Than Ever.



Graphical Analysis
of PK Profiles

GastroPlusGPT™ AI Powered Technical Assistance

What is the difference between the F_a and F in this simulation?

In the current simulation, the distinction between F_a and F is as follows:

- F_a (Fraction Absorbed):** F_a is the percentage of the orally administered dose that is absorbed across the gastrointestinal (GI) epithelium into the enterocytes. It reflects the extent of drug that leaves the gut lumen and enters the enterocytes, regardless of subsequent metabolism or extraction. In your simulation, $F_a = 38.34\%$.
- F (Bioavailability):** F is the overall bioavailability, representing the percentage of the administered dose that reaches the systemic circulation unchanged. It

Parameter	Mean	SD	CV	Min	Max	Q1	Q3	Median	Mode	Skewness	Kurtosis
C _{max}	10.5	2.5	23.8%	5.0	15.0	7.5	12.5	10.0	10.0	0.5	3.0
AUC _{0-∞}	150.0	30.0	20.0%	90.0	210.0	110.0	190.0	150.0	150.0	0.2	2.5
t _{1/2}	4.0	0.5	12.5%	3.0	5.0	3.5	4.5	4.0	4.0	0.1	1.5

Statistical Analysis
of PK Parameters

Level	Clear	Warning	Feedback Type	Description
Information	Done	Summary	Information	The observed AUC _{0-∞} is 150.0 and the observed AUC _{0-∞} is 150.0. The predicted AUC _{0-∞} is 150.0. The AUC is 100% of the observed AUC. There are multiple measures that need to be taken in the situation.
Information	Done	Summary	Information	The predicted AUC _{0-∞} is 150.0 and the observed AUC _{0-∞} is 150.0. The predicted AUC _{0-∞} is 150.0. The AUC is 100% of the observed AUC. There are multiple measures that need to be taken in the situation.

AssessmentsPlus™
Embedded Expert Advice

What's GastroPlus?

GastroPlus is a mechanistically based simulation software package that simulates intravenous and oral absorption, pharmacokinetics, drug-drug interactions, and pharmacodynamics in humans and animals. This integrated platform combines a user-friendly interface with powerful science to help you make faster and more informed project decisions.

What's new in GPX.2?

- **UPDATED** ACATPlus™: more components, more layers, and new science to the top-rated model
- **UPDATED** intramuscular and subcutaneous dosing routes now included
- **NEW** API/R script automation capabilities to create, modify and run GPX™ projects
- **NEW** AI-powered chatbot to answer your technical and operational questions in real-time
- **NEW** embedded expert knowledge for simulation and compound assessments
- **NEW** P-PSD™ functionality to bridge the IVIVR/C gap
- **NEW** DDI standard models and reports
- **NEW** AI-driven data extraction tools
- **EXPANDED** DDI and PBPPlus™ module features including the Distribution Dashboard
- **IMPROVED** virtual bioequivalence trials include full and semi-replicate designs

Rev. 09/05/2025